HCC-话题@MedSci

#HCC#

114篇内容 | 4825人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2238289, encodeId=1f0922382892c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=4efc120614f7' target=_blank style='color:#2F92EE;'>#AASLD2024#</a>, objectTitle=2024 AASLD | STRIDE方案治疗Child-Pugh B级uHCC的真实世界探索, objectType=article, longId=851547, objectId=4a1985154e18, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719539714497_5579292.jpg, objectUrl=/article/show_article.do?id=4a1985154e18, replyNumber=0, likeNumber=25, createdTime=2024-11-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=4a1985154e18, moduleTitle=2024 AASLD | STRIDE方案治疗Child-Pugh B级uHCC的真实世界探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a1985154e18)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2238288, encodeId=36dd223828889, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=71af120514a2' target=_blank style='color:#2F92EE;'>#AASLD 2024#</a>, objectTitle=2024 AASLD | T+A治疗晚期HCC：疗效预测与静脉曲张出血风险探究, objectType=article, longId=851546, objectId=2071851546ef, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241107/1730967184313_8538692.jpg, objectUrl=/article/show_article.do?id=2071851546ef, replyNumber=0, likeNumber=22, createdTime=2024-11-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=2071851546ef, moduleTitle=2024 AASLD | T+A治疗晚期HCC：疗效预测与静脉曲张出血风险探究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2071851546ef)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2236958, encodeId=4ad122369580e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, objectTitle=【会议撷萃】窦晓光教授：如何降低HBV相关HCC, objectType=article, longId=849782, objectId=a856849e8284, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719489899523_2570354.png, objectUrl=/article/show_article.do?id=a856849e8284, replyNumber=0, likeNumber=25, createdTime=2024-11-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=江苏省, moduleDTOList=[ModuleDTO(moduleId=a856849e8284, moduleTitle=【会议撷萃】窦晓光教授：如何降低HBV相关HCC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a856849e8284)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2236142, encodeId=e8f82236142f8, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=d5661393317' target=_blank style='color:#2F92EE;'>#PD1#</a>, objectTitle=CMI：复旦大学团队研究表明靶向GSDME介导的巨噬细胞极化增强肝癌抗肿瘤免疫, objectType=article, longId=850539, objectId=efa6850539f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401030/1730265935847_8538692.jpg, objectUrl=/article/show_article.do?id=efa6850539f2, replyNumber=0, likeNumber=25, createdTime=2024-11-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=efa6850539f2, moduleTitle=CMI：复旦大学团队研究表明靶向GSDME介导的巨噬细胞极化增强肝癌抗肿瘤免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efa6850539f2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2227921, encodeId=c498222e921aa, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=赵卫峰教授：亚厘米肝癌的诊断和鉴别诊断, objectType=article, longId=844848, objectId=0c9784484834, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240624/1719201193789_92910.png, objectUrl=/article/show_article.do?id=0c9784484834, replyNumber=0, likeNumber=118, createdTime=2024-09-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0c9784484834, moduleTitle=赵卫峰教授：亚厘米肝癌的诊断和鉴别诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c9784484834)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2222457, encodeId=72b4222245e21, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=91583e09134' target=_blank style='color:#2F92EE;'>#原发性肝细胞癌#</a>, objectTitle=陆荫英教授：从《专家共识》出发，对晚期HCC进行精细化管理, objectType=article, longId=840591, objectId=092a84059176, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719539714497_5579292.jpg, objectUrl=/article/show_article.do?id=092a84059176, replyNumber=0, likeNumber=103, createdTime=2024-08-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=092a84059176, moduleTitle=陆荫英教授：从《专家共识》出发，对晚期HCC进行精细化管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=092a84059176)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2218171, encodeId=bee022181e1ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a>, objectTitle=专访王晖教授：慢乙肝治疗中，如何实现临床治愈与预防 HCC ？| 第六届东方感染病-肝病会议 2024, objectType=article, longId=837402, objectId=eef383e40266, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722592941403_92910.png, objectUrl=/article/show_article.do?id=eef383e40266, replyNumber=0, likeNumber=73, createdTime=2024-08-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=eef383e40266, moduleTitle=专访王晖教授：慢乙肝治疗中，如何实现临床治愈与预防 HCC ？| 第六届东方感染病-肝病会议 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eef383e40266)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216306, encodeId=af66221630632, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=f7872914569' target=_blank style='color:#2F92EE;'>#免疫联合治疗#</a>, objectTitle=【ASCO 2024】洞察诊疗前沿，看晚期HCC免疫联合治疗新进展, objectType=article, longId=835551, objectId=001b835551d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719539714497_5579292.jpg, objectUrl=/article/show_article.do?id=001b835551d3, replyNumber=0, likeNumber=126, createdTime=2024-07-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=001b835551d3, moduleTitle=【ASCO 2024】洞察诊疗前沿，看晚期HCC免疫联合治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=001b835551d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214909, encodeId=12d9221490980, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=1e47e697672' target=_blank style='color:#2F92EE;'>#索拉非尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=Ann. Oncol ：纳武利尤单抗联合伊匹木单抗：晚期肝细胞癌患者的有效二线治疗方案, objectType=article, longId=834308, objectId=73478343087f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240709/1720504732320_8538692.png, objectUrl=/article/show_article.do?id=73478343087f, replyNumber=0, likeNumber=185, createdTime=2024-07-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=73478343087f, moduleTitle=Ann. Oncol ：纳武利尤单抗联合伊匹木单抗：晚期肝细胞癌患者的有效二线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73478343087f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212768, encodeId=48f92212e683d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=c0293e422ad' target=_blank style='color:#2F92EE;'>#双免疫联合#</a> <a href='/topic/show?id=cf39116169ab' target=_blank style='color:#2F92EE;'>#HIMALAYA研究#</a>, objectTitle=读书报告 | HIMALAYA研究四年总生存期更新, objectType=article, longId=832208, objectId=889b83220883, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719624789928_5579292.jpg, objectUrl=/article/show_article.do?id=889b83220883, replyNumber=0, likeNumber=139, createdTime=2024-07-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=889b83220883, moduleTitle=读书报告 | HIMALAYA研究四年总生存期更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889b83220883)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2204685, encodeId=8c7a220468510, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=e4fe1144e1ce' target=_blank style='color:#2F92EE;'>#A-HCC#</a>, objectTitle=Hepatology：eG副主编高斌教授综述：酒精性肝癌最新进展与未来研究方向, objectType=article, longId=823080, objectId=b53e823080cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240514/1715679836336_5579292.jpg, objectUrl=/article/show_article.do?id=b53e823080cc, replyNumber=0, likeNumber=126, createdTime=2024-05-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b53e823080cc, moduleTitle=Hepatology：eG副主编高斌教授综述：酒精性肝癌最新进展与未来研究方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b53e823080cc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2202028, encodeId=1b952202028c3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=ccc48119e63' target=_blank style='color:#2F92EE;'>#肝动脉化疗栓塞术#</a>, objectTitle=Radiology：增殖型HCC对经动脉化疗栓塞后治疗预后的反应及差异, objectType=article, longId=824577, objectId=7a458245e7f1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=7a458245e7f1, replyNumber=0, likeNumber=80, createdTime=2024-05-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7a458245e7f1, moduleTitle=Radiology：增殖型HCC对经动脉化疗栓塞后治疗预后的反应及差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a458245e7f1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2201354, encodeId=b9372201354d6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, objectTitle=European Radiology：使用RECIST对不可切除HCC进行更准确的治疗反应评估, objectType=article, longId=823959, objectId=17828239595c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867598346_4754896.jpeg, objectUrl=/article/show_article.do?id=17828239595c, replyNumber=0, likeNumber=91, createdTime=2024-05-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=17828239595c, moduleTitle=European Radiology：使用RECIST对不可切除HCC进行更准确的治疗反应评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17828239595c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200547, encodeId=f1f0220054e8c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=dbce1e071e4' target=_blank style='color:#2F92EE;'>#TACE#</a>, objectTitle=European Radiology:TACE联合camrelizumab+阿帕替尼在HCC患者中的实际疗效和安全性评估, objectType=article, longId=823441, objectId=57dc82344176, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=57dc82344176, replyNumber=0, likeNumber=91, createdTime=2024-04-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=57dc82344176, moduleTitle=European Radiology:TACE联合camrelizumab+阿帕替尼在HCC患者中的实际疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57dc82344176)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2199167, encodeId=070b219916e84, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=547e11349346' target=_blank style='color:#2F92EE;'>#质子密度脂肪分数#</a>, objectTitle=European Radiology：磁共振质子密度脂肪分数对HCC脂肪变性的肿瘤分级, objectType=article, longId=822045, objectId=073d822045a3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867598346_4754896.jpeg, objectUrl=/article/show_article.do?id=073d822045a3, replyNumber=0, likeNumber=106, createdTime=2024-04-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=073d822045a3, moduleTitle=European Radiology：磁共振质子密度脂肪分数对HCC脂肪变性的肿瘤分级, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=073d822045a3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196659, encodeId=ebcf2196659be, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=57735e39801' target=_blank style='color:#2F92EE;'>#放射组学#</a>, objectTitle=European Radiology：预测HCC患者化疗栓塞术后预后的CT放射组学列线图, objectType=article, longId=820018, objectId=b8c582001892, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=b8c582001892, replyNumber=0, likeNumber=78, createdTime=2024-04-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b8c582001892, moduleTitle=European Radiology：预测HCC患者化疗栓塞术后预后的CT放射组学列线图, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8c582001892)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193395, encodeId=1581219339501, content=<a href='/topic/show?id=57735e39801' target=_blank style='color:#2F92EE;'>#放射组学#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：CT放射组学在预测HCC患者微血管浸润和生存方面的表现和价值 , objectType=article, longId=817205, objectId=d3f381e205d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240315/1710480821151_1605392.png, objectUrl=/article/show_article.do?id=d3f381e205d3, replyNumber=0, likeNumber=0, createdTime=2024-03-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d3f381e205d3, moduleTitle=European Radiology：CT放射组学在预测HCC患者微血管浸润和生存方面的表现和价值 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3f381e205d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191547, encodeId=2300219154e5d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=f1fc50e88a2' target=_blank style='color:#2F92EE;'>#微血管浸润#</a>, objectTitle=European Radiology：增强超声在预测HCC微血管浸润风险方面的应用及价值, objectType=article, longId=816184, objectId=377281618437, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=377281618437, replyNumber=0, likeNumber=78, createdTime=2024-03-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=377281618437, moduleTitle=European Radiology：增强超声在预测HCC微血管浸润风险方面的应用及价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=377281618437)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190357, encodeId=2500219035eaa, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=1e47e697672' target=_blank style='color:#2F92EE;'>#索拉非尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=Ann. Oncol | 纳武利尤单抗治疗接受索拉非尼初治或经治的晚期肝细胞癌患者：CheckMate 040 的5年随访数据, objectType=article, longId=815324, objectId=7fda81532485, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240229/1709215959435_6145188.png, objectUrl=/article/show_article.do?id=7fda81532485, replyNumber=0, likeNumber=102, createdTime=2024-03-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7fda81532485, moduleTitle=Ann. Oncol | 纳武利尤单抗治疗接受索拉非尼初治或经治的晚期肝细胞癌患者：CheckMate 040 的5年随访数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fda81532485)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188778, encodeId=668e2188e78cf, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a> <a href='/topic/show?id=6e9011142e93' target=_blank style='color:#2F92EE;'>#蛋白降解靶向嵌合物#</a>, objectTitle=樊嘉院士等人发表重磅综述！晚期肝癌治疗有望迎来三类“新武器”！, objectType=article, longId=813994, objectId=139581399430, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=139581399430, replyNumber=0, likeNumber=94, createdTime=2024-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=139581399430, moduleTitle=樊嘉院士等人发表重磅综述！晚期肝癌治疗有望迎来三类“新武器”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=139581399430)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#HCC# #AASLD2024#

2024 AASLD | STRIDE方案治疗Child-Pugh B级uHCC的真实世界探索

2024-11-21发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#HCC# #AASLD 2024#

2024 AASLD | T+A治疗晚期HCC：疗效预测与静脉曲张出血风险探究

2024-11-21发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#HCC# #HBV#

【会议撷萃】窦晓光教授：如何降低HBV相关HCC

2024-11-14发表于江苏省

梅斯管理员 (审核中...)

前往app查看评论内容

#肝细胞癌# #HCC# #PD1#

CMI：复旦大学团队研究表明靶向GSDME介导的巨噬细胞极化增强肝癌抗肿瘤免疫

2024-11-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肝癌# #HCC#

赵卫峰教授：亚厘米肝癌的诊断和鉴别诊断

2024-09-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#专家共识# #HCC# #原发性肝细胞癌#

陆荫英教授：从《专家共识》出发，对晚期HCC进行精细化管理

2024-08-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#HCC# #慢乙肝#

专访王晖教授：慢乙肝治疗中，如何实现临床治愈与预防 HCC ？| 第六届东方感染病-肝病会议 2024

2024-08-02发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肝细胞癌# #HCC# #免疫联合治疗#

【ASCO 2024】洞察诊疗前沿，看晚期HCC免疫联合治疗新进展

2024-07-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#HCC# #索拉非尼# #纳武利尤单抗# #伊匹木单抗#

Ann. Oncol ：纳武利尤单抗联合伊匹木单抗：晚期肝细胞癌患者的有效二线治疗方案

2024-07-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#HCC# #双免疫联合# #HIMALAYA研究#

读书报告 | HIMALAYA研究四年总生存期更新

2024-07-02发表于上海

梅斯管理员 (审核中...)